Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27837835 | 0.79 | ALOX15 (0.38) | EPHX1EPHX2 | |
| SCHEMBL9008707 | 0.76 | EPHX1 (0.52) | EPHX1SIGMAR1CHRM5CHRM3EPHX2 | |
| SCHEMBL23169461 | 0.75 | PKM (0.50) | EPHX1PKMADRA2APDE4AADRA1A | |
| SCHEMBL1313991 | 0.74 | ALDH1A1 (0.39) | EPHX1HPGDALDH1A1 | |
| SCHEMBL16118651 | 0.73 | TSHR (0.42) | EPHX1PKMHPGDKMT2ANPC1 | |
| SCHEMBL16118643 | 0.73 | LMNA (0.53) | EPHX1PKMKMT2ANPC1RAB9A | |
| SCHEMBL249281 | 0.73 | ALOX15 (0.41) | EPHX1 | |
| SCHEMBL785991 | 0.73 | USP30 (0.43) | — | |
| SCHEMBL13369546 | 0.73 | USP30 (0.42) | EPHX1KDM4E | |
| SCHEMBL16099597 | 0.72 | ALDH1A1 (0.58) | EPHX1PKMHPGDKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275670-A1 | New Compounds VII | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | claimed |
| EP-2321276-A1 | NEW COMPOUNDS VII | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | claimed |
| WO-2009147219-A1 | NEW COMPOUNDS VII | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | claimed |
| US-20110275670-A1 | New Compounds VII | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
| EP-2321276-A1 | NEW COMPOUNDS VII | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009147219-A1 | NEW COMPOUNDS VII | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | disclosed |
| US-4370328-A | Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines | PFIZER INC. (US) | 1983-01-25 | — | — | US | disclosed |
| EP-0017411-B1 | PHTHALAZINE CARDIAC STIMULANTS, PROCESSES FOR PREPARING THEM, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pfizer Limited (GB) | 1982-03-31 | — | — | EP | disclosed |
| EP-0017411-A1 | Phthalazine cardiac stimulants, processes for preparing them, and pharmaceutical compositions containing them | Pfizer Limited (GB) | 1980-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275670-A1 | New Compounds VII | GPR119, GLP1R, GIPR | EPHX1 3339/4885SIGMAR1 1999/4885CHRM5 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.